Clinical Pharmacokinetics

, Volume 55, Issue 7, pp 807–812 | Cite as

Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome

  • Stephanie E. Reuter
  • Jennifer H. MartinEmail author
Review Article


Anorexia can affect up to 90 % of people with advanced cancer. It is a complex symptom associated with changes in taste, lack of hunger at mealtimes and lack of food enjoyment. Associated weight loss is part of the physical decline that occurs as cancer worsens. Weight loss can also occur from cachexia, the increased metabolism of energy due to raised inflammatory cytokines, liver metastases and other factors seen in several advanced cancers. Independent of anorexia, although frequently associated (where it is referred to as the cachexia-anorexia syndrome), it accounts for a significant amount of morbidity and deaths in people with cancer. In particular, quality of life for the patient and the family is significantly affected with this syndrome as it causes anxiety and distress. Therefore, it is important that research into therapies is undertaken, particularly focusing on an understanding of the pharmacokinetic properties of compounds in this cachexic population. Cannabinoids are one such group of therapies that have received a large amount of media focus recently. However, there appears to be a lack on rigorous pharmacokinetic data of these complex and varied compounds in the cachexic population. Similarly, there is a lack of pharmacokinetic data in any population group for the non- tetrahydrocannabinol (THC) and cannabidiol (CBD) cannabinoids (often due to the lack of analytical standards for quantification). This review will thus examine the pharmacokinetics of major cannabinoids i.e. THC and CBD in a cancer population. Overall, based on the current literature, evidence for the use of cannabinoids for the treatment of cancer-related cachexia-anorexia syndrome remains equivocal. A high-quality, rigorous, phase I/II study to elicit pharmacokinetic dose–concentration and concentration–response data, with a clinically acceptable mode of delivery to reduce intrapatient variability and enable more consistent bioavailability is needed in this population.


Cancer Cachexia Cannabidiol Nabilone Dronabinol Cannabis Extract 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Compliance with Ethical Standards


No funding was provided for this manuscript. Government funding for rigorous clinical trials in medicinal cannabis use have been provided for research projects in New South Wales, Australia.

Conflicts of interest

Jennifer H. Martin and Stephanie E. Reuter are part of the New South Wales Government-funded phase II project team in clinical pharmacology for a study commencing in 2016. Jennifer H. Martin is funded by the University of Newcastle and Calvary Mater Hospital, NSW, Australia, and Stephanie E. Reuter receives funds from the National Health and Medical Research Council, University of South Australia and University of Newcastle.

Supplementary material

40262_2015_363_MOESM1_ESM.docx (140 kb)
Supplementary material 1 (DOCX 140 kb)


  1. 1.
    Reid J, McKenna H, Fitzsimons D, McCance T. The experience of cancer cachexia: a qualitative study of advanced cancer patients and their family members. Int J Nurs Stud. 2009;46(5):606–16.CrossRefPubMedGoogle Scholar
  2. 2.
    Poole K, Froggatt K. Loss of weight and loss of appetite in advanced cancer: a problem for the patient, the carer, or the health professional? Palliat Med. 2002;16(6):499–506.CrossRefPubMedGoogle Scholar
  3. 3.
    Mantovani G, Madeddu C. Cancer cachexia: medical management. Support Care Cancer. 2010;18(1):1–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol. 2005;23(33):8500–11.CrossRefPubMedGoogle Scholar
  5. 5.
    Miller S, McNutt L, McCann MA, McCorry N. Use of corticosteroids for anorexia in palliative medicine: a systematic review. J Palliat Med. 2014;17(4):482–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Ruiz Garcia V, Lopez-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2013;3:CD004310.Google Scholar
  7. 7.
    Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers. 2007;4(8):1614–48.CrossRefPubMedGoogle Scholar
  8. 8.
    Engeli S. Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. Handb Exp Pharmacol. 2012;209:357–81.CrossRefPubMedGoogle Scholar
  9. 9.
    Pichard C, Kyle U. Body composition measurements during wasting diseases. Curr Opin Clin Nutr Metab Care. 1998;1(4):357–61.CrossRefPubMedGoogle Scholar
  10. 10.
    Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770–804.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327–60.CrossRefPubMedGoogle Scholar
  12. 12.
    Lindgren JE, Ohlsson A, Agurell S, Hollister L, Gillespie H. Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Psychopharmacology. 1981;74(3):208–12.CrossRefPubMedGoogle Scholar
  13. 13.
    Huestis MA, Sampson AH, Holicky BJ, Henningfield JE, Cone EJ. Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther. 1992;52(1):31–41.CrossRefPubMedGoogle Scholar
  14. 14.
    Ohlsson A, Widman M, Carlsson S, Ryman T, Strid C. Plasma and brain levels of delta 6-THC and seven monooxygenated metabolites correlated to the cataleptic effect in the mouse. Acta Pharmacol Toxicol (Copenh). 1980;47(4):308–17.CrossRefPubMedGoogle Scholar
  15. 15.
    Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther. 1983;34(3):352–63.CrossRefPubMedGoogle Scholar
  16. 16.
    Guy GW, Robson PJ. A phase I, double-blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers. J Cannabis Ther. 2003;3(4):121–51.CrossRefGoogle Scholar
  17. 17.
    Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem. 2011;57(1):66–75.CrossRefPubMedGoogle Scholar
  18. 18.
    Agurell S, Leander K. Stability, transfer and absorption of cannabinoid constituents of cannabis (hashish) during smoking. Acta Pharm Suec. 1971;8(4):391–402.PubMedGoogle Scholar
  19. 19.
    Hunt CA, Jones RT. Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther. 1980;215(1):35–44.PubMedGoogle Scholar
  20. 20.
    Kreuz DS, Axelrod J. Delta-9-tetrahydrocannabinol: localization in body fat. Science. 1973;179(4071):391–3.CrossRefPubMedGoogle Scholar
  21. 21.
    Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014;46(1):86–95.CrossRefPubMedGoogle Scholar
  22. 22.
    Heuberger JA, Guan Z, Oyetayo OO, Klumpers L, Morrison PD, Beumer TL, et al. Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics. Clin Pharmacokinet. 2015;54(2):209–19.CrossRefPubMedGoogle Scholar
  23. 23.
    Trobec K, Kerec Kos M, von Haehling S, Springer J, Anker SD, Lainscak M. Pharmacokinetics of drugs in cachectic patients: a systematic review. PLoS One. 2013;8(11):e79603.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Barry RE. Malignancy, weight loss, and the small intestinal mucosa. Gut. 1074;15(7):562–70.CrossRefGoogle Scholar
  25. 25.
    King D, Smith ML, Chapman TJ, Stockdale HR, Lye M. Fat malabsorption in elderly patients with cardiac cachexia. Age Ageing. 1996;25(2):144–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Fearon K, Preston T. Body composition in cancer cachexia. Infusionstherapie. 1990;17(Suppl 3):63–6.PubMedGoogle Scholar
  27. 27.
    Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos. 2008;36(2):205–16.CrossRefPubMedGoogle Scholar
  28. 28.
    Herrington JD, Tran HT, Riggs MW. Prospective evaluation of carboplatin AUC dosing in patients with a BMI> or = 27 or cachexia. Cancer Chemother Pharmacol. 2006;57(2):241–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Mouly S, Aymard G, Diquet B, Caulin C, Bergmann JF. Oral ganciclovir systemic exposure is enhanced in HIV-infected patients with diarrhea and weight loss. J Acquir Immune Defic Syndr. 2000;24(4):344–51.CrossRefPubMedGoogle Scholar
  30. 30.
    Cvan Trobec K, Kerec Kos M, Trontelj J, Grabnar I, Tschirner A, Palus S, et al. Influence of cancer cachexia on drug liver metabolism and renal elimination in rats. J Cachexia Sarcopenia Muscle. 2015;6(1):45–52.Google Scholar
  31. 31.
    Trauner M, Fickert P, Stauber RE. Inflammation-induced cholestasis. J Gastroenterol Hepatol. 1999;14(10):946–59.CrossRefPubMedGoogle Scholar
  32. 32.
    Slaviero K, Clarke SJ, Rivory L. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol. 2003;4(4):224–32.CrossRefPubMedGoogle Scholar
  33. 33.
    Timpone JG, Wright DJ, Li N, Egorin MJ, Enama ME, Mayers J, et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. AIDS Res Hum Retrovir. 1997;13(4):305–15.CrossRefPubMedGoogle Scholar
  34. 34.
    Ekert H, Waters KD, Jurk IH, Mobilia J, Loughnan P. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. Med J Aust. 1979;2(12):657–9.PubMedGoogle Scholar
  35. 35.
    Regelson W, Butler J, Schulz J, Kirk T, Peek L, Green M. Delta-9-tetrahydrocannabinol (delta-9-THC) as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. In: Braude MS, Szara S, editors. In: Proceedings of an International Conference on the Pharmacology of Cannabis. New York: Raven Press; 1975. p. 269–87.Google Scholar
  36. 36.
    Nelson K, Walsh D, Deeter P, Sheehan F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care. 1994;10(1):14–8.PubMedGoogle Scholar
  37. 37.
    Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with dronabinol. Pharmacol Biochem Behav. 1991;40(3):695–700.CrossRefPubMedGoogle Scholar
  38. 38.
    Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage. 1995;10(2):89–97.CrossRefPubMedGoogle Scholar
  39. 39.
    Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002;20(2):567–73.CrossRefPubMedGoogle Scholar
  40. 40.
    Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol. 2006;24(21):3394–400.CrossRefPubMedGoogle Scholar
  41. 41.
    Radbruch L, Elsner F, Trottenberg P, Strasser F, Fearon K. Clinical practice guidelines on cancer cachexia in advanced cancer patients. Aachen: Department of Palliative Medicine/European Palliative Care Research Collaborative; 2010.Google Scholar
  42. 42.
    Brisbois TD, de Kock IH, Watanabe SM, Mirhosseini M, Lamoureux DC, Chasen M, et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol. 2011;22(9):2086–93.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.School of Pharmacy and Medical SciencesUniversity of South AustraliaAdelaideAustralia
  2. 2.Sansom Institute for Health ResearchUniversity of South AustraliaAdelaideAustralia
  3. 3.Department of Clinical PharmacologyUniversity of NewcastleWaratahAustralia

Personalised recommendations